Aflac AFL Cancer — Effect of change in discount rate assumptions
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — effect of change in discount rate assumptions.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aflac's cancer — effect of change in discount rate assumptions?
- Aflac (AFL) reported cancer — effect of change in discount rate assumptions of -$2.47B in Q1 2026.
- How has Aflac's cancer — effect of change in discount rate assumptions changed year-over-year?
- Aflac's cancer — effect of change in discount rate assumptions decreased by 260.6% year-over-year, from $1.54B to -$2.47B.
- What is the long-term trend for Aflac's cancer — effect of change in discount rate assumptions?
- Over 2 years (2023 to 2025), Aflac's cancer — effect of change in discount rate assumptions has grown at a -87.7% compound annual growth rate (CAGR), from $29.5B to $449M.
- What does cancer — effect of change in discount rate assumptions mean?
- This metric quantifies the impact on the present value of future policy benefit liabilities resulting from adjustments to the discount rate used for actuarial calculations. Changes in this rate reflect shifts in the economic environment, such as interest rate trends, which directly alter the required reserves for the cancer segment. It is a key indicator of how sensitive the segment's liability profile is to macroeconomic interest rate volatility.